Preclinical R&D services

Since 2001 Pharmahungary Group has been offering global services focusing on in vivo and in vitro models of cardiovascular, metabolic, renal, inflammation, oncology, musculoskeletal, and women’s health diseases. Pharmahungary Groups has demonstrated capabilities to accomplish preclinical studies with excellent records of client satisfaction regarding quality, timelines, and budgets in over 350 development projects including drugs and medical devices. Our innovative R&D services include in vitro and in vivo efficacy models with cardiac cells, small and large animal models of cardiovascular, metabolic, renal (myocardial infarction, heart failure, arrhythmias, diabetes, insulin resistance, hyperlipidemia, atherosclerosis, uremia, obesity, etc.), inflammation, oncology (triple-negative breast cancer, small-cell lung cancer), musculoskeletal (sarcopenia), and women’s health diseases. Custom-designed and cardiovascular co-morbidity models such as myocardial infarction with risk factors and co-morbidities such as hyperlipidemia and diabetes are also available. We are also providing a unique service, i.e. small and large animal multicenter studies for myocardial infarction and heart failure performed in an international consortium in order to generate more robust data for your drug candidates. Our novel cardiac safety testing platform hiddentox™ involving combined experimental models of cardiac diseases (especially myocardial ischemia/reperfusion and ischemic conditioning) in the presence and absence of major cardiovascular comorbidities and/or cotreatments is also available.